Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
LAG-3
Pharma
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
BMS revealed that a phase 3 trial of Opdualag in patients with completely resected stage III/IV melanoma did not achieve its primary endpoint.
Kevin Dunleavy
Feb 14, 2025 8:15am
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
Bristol Myers’ top challenges, as seen by analysts
Jul 12, 2024 12:00pm
Regeneron's Libtayo delivers lung cancer win with BMS' Yervoy
Dec 1, 2022 12:25pm
ASCO: BMS offers closer look at Opdualag's LAG-3 melanoma win
May 26, 2022 5:00pm
BMS opens 3rd checkpoint inhibitor class
Mar 18, 2022 7:23pm
